Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$25.76-13.2%$11.51$6.48▼$37.38$319.60M0.55441,646 shs4.77 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics0.00%+202.70%+132.26%+132.07%+58.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNKTRNektar Therapeutics4.5865 of 5 stars3.55.00.04.23.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 3.00Buy$84.17226.73% UpsideCurrent Analyst Ratings BreakdownLatest NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.005/12/2025NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform4/11/2025NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00 ➝ $30.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$98.43M3.25N/AN/A$4.94 per share5.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)Latest NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A3.243.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics3.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22012.41 million11.95 millionOptionableNKTR HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Estimate for NKTR Q2 Earnings?June 29 at 2:19 AM | americanbankingnews.comNektar Jumps 157% on Drug Trial Data-Can It Go Even Higher?June 28 at 12:46 PM | msn.comNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?...June 28 at 8:15 AM | marketbeat.comNektar Therapeutics Regains Nasdaq Compliance by June 2025June 27 at 6:10 PM | tipranks.comNektar Therapeutics Scores Big Phase 2b Win With RezpegJune 27 at 9:13 AM | seekingalpha.comHC Wainwright Analysts Boost Earnings Estimates for NKTRJune 27 at 6:19 AM | marketbeat.comResearch Analysts Set Expectations for NKTR Q1 EarningsJune 26 at 6:52 AM | marketbeat.comRhumbline Advisers Purchases 41,948 Shares of Nektar Therapeutics (NASDAQ:NKTR)June 26 at 3:12 AM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 26 at 2:57 AM | americanbankingnews.comWhy Nektar Therapeutics Stock Was Red-Hot TodayJune 25, 2025 | fool.comNektar Therapeutics (NKTR) Jumps as Eczema Trial SucceedsJune 25, 2025 | gurufocus.comNektar Therapeutics surge continues as stock up another 25%June 25, 2025 | seekingalpha.comWhy Is Nektar Therapeutics Stock Trading Higher On Wednesday?June 25, 2025 | benzinga.comNKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis StudyJune 25, 2025 | zacks.comNKTR stock today: Surges 12.1% on positive eczema trial dataJune 25, 2025 | fingerlakes1.comFNektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts UnconvincedJune 25, 2025 | biospace.comBInvestors sweet on Nektar as phase 2b eczema success doubles share priceJune 25, 2025 | fiercebiotech.comFNektar Therapeutics stock soars after atopic dermatitis drug hits key targetsJune 25, 2025 | ca.investing.comNektar Therapeutics (NKTR) Jumps 116% in Premarket After Positive Trial ResultsJune 24, 2025 | tokenist.comTNektar Therapeutics Soars 86% After Eczema Drug Hits Midstage Trial GoalsJune 24, 2025 | financialbuzz.comFNektar Therapeutics rockets on positive trial resultsJune 24, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?NKTR Company DescriptionsNektar Therapeutics NASDAQ:NKTR$25.76 -3.92 (-13.21%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$26.00 +0.24 (+0.95%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
